Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)- one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 322-330

  Regan, Christopher P ^a   Kiss, Laszlo ^a   Stump, Gary L ^a   McIntyre, Charles J ^a   Beshore, Douglas C ^a   Liverton, Nigel J ^a   Dinsmore, Christopher J ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; 2 PHENYL 1,1 DIPYRIDIN 3 YL 2 PYRROLIDIN 1 YL ETHANOL; 3 [(DIMETHYLAMINO)METHYL] 6 METHOXY 2 METHYL 4 PHENYLISOQUINOLIN 1(2H) ONE; ANTIARRHYTHMIC AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; PROPAFENONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; REFRACTORY PERIOD; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BENZOPYRANS; CELL LINE; DOGS; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; ISOQUINOLINES; KV1.5 POTASSIUM CHANNEL; MALE; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PROPAFENONE; PYRIDINES; SODIUM CHANNEL BLOCKERS;

EID: 37349055424     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127654     Document Type: Article

References (40)

1. Beatch GN, Helmes M, Blaauw Y, and Allessie MA (2004) Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria-selective antiarrhythmic drug, RSD1235, in the goat. Circulation 110:III-163.
2. Beatch GN, Shinagawa K, Johnson B, Jung G, Plouvier B, Zolotoy A, Ezrin AM, Walker MJA, and Nattel S (2002) RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. PACE 25:698.
3. Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, and Allessie MA (2004) "Early" class III drugs for the treatment of atrial fibrillation. Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 110:1717-1724.
4. Cardin S, Li D, Thorin-Trescases N, Leung T-K, Thorin E, and Nattel S (2003) Evolution of the atrial fibrillation substrate in experimental congestive heart failure. Angiotensin-dependent and independent pathways. Cardiovasc Res 60:315-325.
5. Cha T-J, Ehrlich JR, Zhang L, Shi Y-F, Tardif J-C, Leung T-K, and Nattel S (2004) Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 109:412-418.
6. Daoud E, Bogun F, Goyal R, Harvey M, Man KC, Strickberger A, and Morady F (1996) Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 94:1600-1606.
7. Decher N, Kumar P, Gonzales T, Pirard B, and Sanguinetti MC (2006) Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol 70:1204-1211.
8. Derakhchan K, Li D, Courtemanche M, Smith B, Brouillette J, Page PL, and Nattel S (2001) Method for simultaneous epicardial and endocardial mapping of in vivo canine heart. Application to atrial conduction properties and arrhythmia mechanisms. J Cardiovasc Electrophysiol 12:548-555.
9. Everett TH, Li H, Mangrum JM, McRury ID, Mitchell MA, Redick JA, and Haines DE (2000) Electrical, morphological and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 102:1454-1460.
10. Everett TH, Wilson EE, Verheule S, Guerra JM, Foreman S, and Olgin JE (2006) Structural atrial remodeling alters the substrate and spatiotemporal organization of atrial fibrillation: a comparison in canine models of structural and electrical atrial remodeling. Am J Physiol 291:H2911-H2923.
11. + current in canine atrial myocytes. Circ Res 93:744-751.
12. Fedida D, Orth PMR, Chen JYC, Lin S, Plouvier B, Jung G, Ezrin AM, and Beatch GN (2005) The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 16:1227-1238.
13. Feng J, Xu D, Wang Z, and Nattel S (1998) Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol 275:H1717-H1725.
14. Gaspo R, Bosch RF, Talajic M, and Nattel S (1997) Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation 96:4027-4035.
15. Hanna N, Cardin S, Leung T-K, and Nattel S (2004) Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 63:236-244.
16. Kingma JH and Suttorp MJ (1992) Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone and verapamil. Am J Cardiol 70:56A-61A.
17. Knobloch K, Brendel J, Peukert S, Rosenstein B, Busch AE, and Wirth KJ (2002) Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left vs right pig atrium in vivo comparison with the IKr blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 366:482-487.
18. + channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther 317:1054-1063.
19. Li D, Benardeau A, and Nattel S (2000a) Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 102:104-112.
20. Li D, Fareh S, Leung T-K, and Nattel S (1999) Promotion of atrial fibrillation by heart failure in dogs. Atrial remodeling of a different sort. Circulation 100:87-95.
21. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, and Nattel S (2000b) Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101:2613-2638.
22. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, and Nattel S (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608-2614.
23. Lynch JJ Jr, Wallace AA, Stupienski RF, Baskin EP, Beare C, Appleby SD, Salata JJ, Jurkiewicz NK, Sanguinetti MC, Stein RB, et al. (1994) Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. J Pharmacol Exp Ther 269: 541-554.
24. Matsuda T, Masmiya H, Tanaka N, Yamashita T, Tsuruzoe N, Tanaka Y, Tanaka H, and Shigenoba K (2001) Inhibition by a novel antiarrhythmic agent, NIP-142, of cloned human cardiac K channel Kv1.5 current. Life Sci 68:2017-2024.
25. Miyata A, Zipes DP, Hall S, and Rubart M (2002) KB-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation 106:1410-1419.
26. Morillo CA, Klein GJ, Jones DL, and Guiraudon CM (1995) Chronic rapid atrial pacing. Structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 91:1588-1595.
27. Nagasawa H, Fujiki A, Fujikura N, Matsuda T, Yamashita T, and Inoue H (2002) Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ J 66:185-191.
28. Nattel S and Carlsson L (2006) Innovative approaches to antiarrhythmic drug therapy. Nat Rev Drug Discov 5:1034-1049.
29. Nattel S, DeBlasio E, Beatch GN, and Wang W-Q (2001) RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Eur Heart J 22 (Suppl. S):448.
30. Nattel S, Shiroshita-Takeshita A, Brundel BJJM, and Rivard L (2005) Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis 48:9-28.
31. Kur blocker, ISQ-1, in rat, dog and nonhuman primate. J Cardiovasc Pharmacol 49:236-245.
32. Ryu K, Shroff S, Sahadevan J, Martovitz N, Khrestian CM, and Stambler BS (2005) Mapping of atrial activation during sustained atrial fibrillation in dogs with rapid ventricular pacing induced heart failure. Evidence for a role of driver regions. J Cardiovasc Electrophysiol 16:1348-1358.
33. Shi Y, Ducharme A, Li, Gaspo R, Nattel S, and Tardif J-C (2001) Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 52:217-225.
34. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung T-K, and Nattel S (2003) Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107:1930-1936.
35. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 315:1362-1367.
36. Trotter BW, Nanda KK, Kett NR, Regan CP, Lynch JJ, Stump GL, Kiss L, Wang J, Spencer RH, Kane SA, et al. (2006) Design and synthesis of 3-cyanoisoquinolines as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J Med Chem 49:6954-6957.
37. Valderrama AL, Dunbar SB, and Mensah GA (2005) Atrial fibrillation. Public health implications. Am J Prev Med 29 (5 Suppl 1):75-80.
38. Waldo AL (2006) A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet medical need. Am Heart J 151:771-778.
39. Wang J, Della Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, Bennett PB, and Salata JJ (2003) Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol 284:H256-H267.
40. + current similar to Kv1.5 cloned channel currents. Circ Res 73:1061-1076.